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Abstract
Murine models have highlighted the importance of T-cells and TH2 cytokines in development of
allergen-induced airway disease. In contrast, the role of mast cells for the development of allergic
airway disease has been controversial. Recent studies in murine models demonstrate a significant
contribution of mast cells during the development of airway hyperresponsiveness and airway
inflammation. Furthermore these models have allowed identifying certain mast cell-produced
mediators (e.g. histamine and leukotriene B4) to be involved in the recruitment of effector T-cells
into the lung. Additionally, mast cell-produced TNF can directly activate TH2 cells and contribute
to the development of allergic airway disease. These new findings demonstrate a complex role of
mast cells and their mediators, not only as effector cells, but also during sensitization and
development of allergic airway disease. Therefore mast cells and certain mast cell-produced
mediators might be an interesting target for the prevention and treatment of allergic asthma.
Introduction
For decades mast cells have been known as important
effector cells for adaptive immune responses. Functions of
mast cells include both IgE-dependent mucosal immunity
to parasites but also dysregulated allergic responses to
environmental antigens. In patients with allergic asthma,
allergen-specific activation of mast cells through IgE
bound to the high-affinity IgE receptor (FcΕRI) induces
early airway responses following allergen exposure. Also
increased numbers of mast cells are found in close prox-
imity to airway smooth muscle in patients with allergic
asthma, suggesting their potential role in the develop-
ment and maintenance of allergic airway disease [1].
Murine models have helped to gain insights into the patho-
genesis of airway inflammation and airway responsiveness
[2]. These models have highlighted the importance of T-
cells and T-cell mediated cytokines for the development of
the disease. Mast cell-deficient mice can be utilized to inves-
tigate the role of mast cells in these models. Most com-
monly two mast cell-deficient mouse strains, the WBBF1-
KitW/KitW-v and more recently the C57BL/6-KitW-sh/KitW-sh
are used [3]. Both strains are mast cells-deficient but also
lack melanocytes. Additionally, the WBBF1-KitW/KitW-v
mice are sterile, anaemic, and lack intestinal cells of Cajal,
whereas the C57BL/6-KitW-sh/KitW-sh are not sterile or anae-
mic [3].
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Mast cells contribute to the development of 
allergic airway disease
The role of mast cells for the development of allergic air-
way disease in murine models is critically dependent on
the sensitization and allergen exposure protocol. In stud-
ies using systemic sensitization with adjuvant hyperre-
sponsiveness (AHR) and airway inflammation are similar
in mast cell- or IgE-deficient mice compared to wild-type
mice [4-6]. However, in models with less potent sensitiza-
tion protocols, a role of mast cells for the induction of
non-allergic [7] but also allergen-induced airway disease
[8-10] can be demonstrated. In these models the presence
of mast cells in already sensitized animals is essential for
the initiation of airway inflammation and AHR. Further
studies, using mast cell reconstitution protocols, revealed
that the expression of the Fc receptor γ chain in mast cells
[10], necessary for the surface expression of the Fcγ recep-
tors I and III and the FcεRI receptor is pivotal for the
induction of most features of allergen-induced lung
pathology. In studies using an inhalation allergen expo-
sure, development of increased airway reactivity was asso-
ciated with the expression of FcεRI on mast cells [11].
These results underscore that mast cells are involved in the
development of an allergic airway disease in already sen-
sitized hosts.
Mast cells not only play an important role during the
effector phase of allergic airway disease but also could be
involved during sensitization to an allergen. Intranasal
exposure with allergen alone does not induce a specific T-
cell response. In contrast, exposure with allergen in com-
bination with a low dose of bacterial lipopolysaccharides
(LPS) induces a specific T-cell response [12] and consecu-
tive challenge with the allergen then leads to eosinophilic
airway inflammation. Interestingly, mast cell-deficient
mice exposed intranasally with allergen and low dose LPS
do not develop eosinophilic airway inflammation follow-
ing rechallenge. However, mast cell-deficient mice recon-
stituted with wild-type mast cells developed airway
inflammation similar to wild-type animals, suggesting an
involvement of mast cells during the sensitization process
[13]. Indeed, mast cells express several Toll like receptors
(TLR) including TLR-4 on their surface and release
cytokines and chemokines following exposure to TLR-lig-
ands [14] and mast cell-deficient mice reconstituted with
TLR-4 deficient mast cells, did not develop airway eosi-
nophilia following allergen exposure [13]. These findings
suggest that IgE-independent mast cell activation through
TLR-4 is necessary for sensitization to an allergen admin-
istered directly into the lung, further extending the func-
tion and role of mast cells in the development of allergic
diseases.
Mast cell-produced mediators
Mast cells, following activation, degranulate and produce
a plethora of lipid mediators, cytokines, and chemokines
[3]. Several of these mediators might contribute through
different mechanisms to the development of AHR. One
potential mechanism could be the secretion of cytokines
and especially IL-13 [15]. IL-13 is capable to directly
induce AHR and blockade of IL-13 has been shown to be
an effective treatment approach in acute [16,17] and
chronic [18] models of allergic airway disease. However,
IL-13 deficient mast cells, when transferred into FcεRI-
receptor deficient mice, where still able to induce
increased airway reactivity. This finding suggests that IL-
13 production from mast cells does not play a primary
role in the development of allergic airway disease [11].
Other mechanisms could be the secretion of chemo-
attractants and chemokines, which lead to the recruitment
of other cell populations, such as effector T-cell into the
lung and airways. Recently an interaction with mast cells
has been described for allergen specific CD8-positive T-
effector cells. These in vitro studies have shown that migra-
tion of CD8-positive T-effector cells can be initiated by
mast cell activation. Furthermore T-cell migration was reg-
ulated by leukotriene B4 (LTB4) produced by mast cells
and the expression of the receptor 1 (BLT-1) on the T-cells
[19]. CD8-positive T-cells [20,21] and especially allergen
experienced CD8-positive T effector cells (Teff) are critical
for the development of AHR and airway inflammation
[22]. Following sensitization and challenge increased
migration of these cells into the lung can be demonstrated
[22] and this migration is dependent on LTB4 [23]. The
contribution of mast cell produced LTB4 for Teff cell
recruitment was assessed in a previously described model
of passive sensitization [24]. Mice were passively sensi-
tized with OVA-specific IgE. Mast cell-, FcεRI- and CD8-
deficient mice showed only low airway reactivity follow-
ing passive sensitization compared to passively sensitized
wild-type mice. Increased airway reactivity could be
reconstituted in CD8-deficient mice by adoptive transfer
of allergen-specific Teff cells. Only transferred BLT-1
expressing Teff migrated effectively to the lung and recon-
stituted AHR whereas BLT-1 deficient Teff failed to do so
[25]. A potential contribution of basophils in this
response can not be excluded as basophils express the
FcΕRI in the mouse [26].
Also other mast cell-produced mediators are of interest.
Histamine receptor 1 has recently been shown to be
important for the development of allergic airway disease
and also for T-cell trafficking [27]. Another important
mast cell-produced mediator is Tumor Necrosis Factor
(TNF). In other disease models mast cell-derived TNF is
important for the induction and promotion of initial
inflammatory events [28-33]. Several studies have alsoJournal of Occupational Medicine and Toxicology 2008, 3(Suppl 1):S2 http://www.occup-med.com/content/3/S1/S2
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demonstrated a contribution of TNF to the induction of
allergic airway diseases [34-36]. Sensitized mast cell-defi-
cient mice express lower levels of TNF in BAL fluid com-
pared to sensitized and challenged wild-type mice and
reconstitution with bone marrow-derived mast cells
restored BAL fluid levels of TNF and AHR [37]. In a recent
study Nakae et al. directly evaluated the role of mast cell-
produced TNF for the induction of allergic airway disease
using a mast cell reconstitution model. Similar to previ-
ous studies, mast cell-deficient animals fail to develop
allergic airway disease whereas mice reconstituted with
mast cells derived from wild-type mice developed allergic
airway disease. In contrast, mice reconstituted with mast
cells derived from TNF-deficient donors have less airway
inflammation and AHR, demonstrating that mast cell-
produced TNF is pivotal for the induction of allergic air-
way disease [38]. Furthermore the authors point out an
enhanced proliferation of TH2 cells induced by mast cell-
produced TNF, suggesting that mast cells induce activa-
tion of allergen specific T-cells in the sites of inflamma-
tion. These findings are of clinical interest as recent studies
in patients with moderate [39] and also more severe
asthma [40,41] described beneficial effects of treatment
with TNF neutralizing antibodies on lung function and
airway reactivity.
Conclusion
Recent studies have outlined a critical role of mast cells for
the development of acute allergic airway disease, espe-
cially in sensitization protocols without an adjuvant. Fur-
thermore there is evidence that mast cells are also
involved during the sensitization to inhaled allergens by
IgE-independent activation through TLR. Still little is
known about the role of the different mediators produced
and secreted by mast cells. Several mast cell-produced
mediators like LTB4, histamine and TNF have been iden-
tified to contribute to the development of allergic airway
disease. Further research is needed as increasing knowl-
edge about these pathways might allow a more targeted
therapy of allergic asthma.
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